Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Susan S. Devesa is active.

Publication


Featured researches published by Susan S. Devesa.


Cancer | 1998

Changing patterns in the incidence of esophageal and gastric carcinoma in the United States

Susan S. Devesa; William J. Blot; Joseph F. Fraumeni

Incidence rates for esophageal adenocarcinoma previously were reported to be increasing rapidly, especially among white males. Rates for gastric cardia adenocarcinoma also were observed to be rising, although less rapidly. In this article, the authors update the incidence trends through 1994 and further consider the trends by age group.


International Journal of Cancer | 2000

International trends and patterns of prostate cancer incidence and mortality

Ann W. Hsing; Lilian Tsao; Susan S. Devesa

Prostate cancer is the most commonly diagnosed cancer in western men, and incidence is rising rapidly in most countries, including low‐risk populations. Age‐adjusted incidence and mortality rates from 15 and 13 countries between 1973–77 and 1988–92, respectively, were compared to provide leads for future analytic studies. Large increases in both incidence and mortality rates of prostate cancer were seen for all countries. For incidence, increases were more pronounced in the United States, Canada, Australia, France and the Asian countries, while the increases in medium‐risk countries were moderate. Increases in incidence ranged from 25%–114%, 24%–55% and 15%–104% in high‐, medium‐ and low‐risk countries, respectively. Mortality rates rose more rapidly in Asian countries than in high‐risk countries. Substantial differences in incidence and mortality across countries were evident, with U.S. blacks having rates that were 50–60 times higher than the rates in Shanghai, China. Increasing incidence rates in the United States and Canada are likely to be due in part to the widespread use of transurethral resection of the prostate and prostate‐specific antigen testing, while increases in the Asian countries are probably related to westernization in these low‐risk populations. The large disparities in incidence between high‐ and low‐risk countries may be due to a combination of genetic and environmental factors. Future studies are needed to examine gene‐gene and gene‐environment interactions in various countries concurrently to shed light on the etiology of prostate cancer and to help elucidate reasons for the large differences in risk between populations. Int. J. Cancer 85:60–67, 2000.


Surgical Oncology Clinics of North America | 2002

Epidemiologic trends in esophageal and gastric cancer in the United States

Linda Morris Brown; Susan S. Devesa

Use of tobacco, moderate to heavy alcohol ingestion, infrequent consumption of raw fruits and vegetables, and low income accounted for more [figure: see text] than 98% of the SCE rates among both African American and white men and for 99% of the excess incidence among African Americans compared to whites in a case-control study in three areas of the United States [14]. Thus, it is likely that declines in the prevalence of smoking and drinking, especially among men, and increased intake of fresh fruits and vegetables may have contributed to the downward incidence and mortality rate trends reported for SCE. In addition, it seems plausible that obesity, GERD, and possibly reductions in H. pylori prevalence have contributed to the upward trends in ACE rates. Reductions in smoking, improved diet, and reductions in H. pylori prevalence probably have contributed to the consistent reductions observed for NGA. Contributing factors are less clear for the rising incidence rates of GCA during the 1970s and 1980s. These incidence rates have not continued to rise in recent years.


Blood | 2009

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

Porcia T. Bradford; Susan S. Devesa; William F. Anderson; Jorge R. Toro

There have been no prior large population-based studies focusing on cutaneous lymphomas (CL) in the United States. Using the Surveillance, Epidemiology and End Results (SEER) program data, we analyzed age-adjusted CL incidence rates (IRs) and survival rates by sex and race/ethnicity. There were 3884 CLs diagnosed during 2001-2005. Cutaneous T-cell lymphomas (CTCLs) accounted for 71% (age-adjusted incidence rate [IR] = 7.7/1 000 000 person-years), whereas cutaneous B-cell lymphomas(CBCLs) accounted for 29% (IR = 3.1/1 000 000 person-years). Males had a statistically significant higher IR of CL than females (14.0 vs 8.2/1 000 000 person-years, respectively; male-female IR ratio [M/F IRR] = 1.72; P < .001). CL IRs were highest among blacks and non-Hispanic whites (both 11.5/1 000 000 person-years), followed by Hispanic whites (7.9) and Asian/Pacific Islanders (7.1). The CTCL IR was highest among blacks (10.0/1 000 000 person-years), whereas the CBCL IR was highest among non-Hispanic whites (3.5). Over the past 25 years, the CL IR increased from 5.0/1 000 000 person-years during 1980-1982 to 14.3 during 2001-2003. During 2004-2005, the CL IR was 12.7. This recent apparent change could be incomplete case ascertainment or potential leveling off of IRs. CLs rates vary markedly by race and sex, supporting the notion that they represent distinct disease entities.


International Journal of Cancer | 2001

International trends and patterns of primary liver cancer

Katherine A. McGlynn; Lilian Tsao; Ann W. Hsing; Susan S. Devesa; Joseph F. Fraumeni

Primary liver cancer (PLC) is common in many areas of the developing world, but uncommon in most of the developed world. Some evidence suggests, however, that the global pattern of PLC may be changing. To clarify this issue, we examined incidence rates for PLC over the 15‐year time period, 1978–92, in selected cancer registries around the world. With some exceptions, developed countries have experienced PLC increases in incidence whereas developing countries have experienced declines. Although the reasons for the trends are not entirely clear, the increased seroprevalence of HCV in the developed world and the elimination of HBV‐cofactors in the developing world are likely to have contributed to the patterns. Further progress against PLC may be seen in the developing world once the HBV‐vaccinated segment of the population reaches adulthood. Published 2001 Wiley‐Liss, Inc.


Cancer | 2004

Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000

Sophia S. Wang; Mark E. Sherman; Allan Hildesheim; James V. Lacey; Susan S. Devesa

Although cervical carcinoma incidence and mortality rates have declined in the U.S. greatly since the introduction of the Papanicolaou smear, this decline has not been uniform for all histologic subtypes. Therefore, the authors assessed the differential incidence rates of squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the cervix by race and disease stage for the past 25 years.


Cancer | 2003

Trends in the incidence of testicular germ cell tumors in the United States

Katherine A. McGlynn; Susan S. Devesa; Alice J. Sigurdson; Linda Morris Brown; Lilian Tsao; Robert E. Tarone

Recent reports have suggested that the increasing rates of testicular germ cell tumors in some populations have begun to plateau. This study was conducted to examine whether rates among white men in the United States have begun to stabilize and whether rates among black men in the United States have remained low.


Blood | 2012

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007

Graça M. Dores; Susan S. Devesa; Rochelle E. Curtis; Martha S. Linet; Lindsay M. Morton

Since 2001, the World Health Organization classification for hematopoietic and lymphoid neoplasms has provided a framework for defining acute leukemia (AL) subtypes, although few population-based studies have assessed incidence patterns and patient survival accordingly. We assessed AL incidence rates (IRs), IR ratios (IRRs), and relative survival in the United States (2001-2007) in one of the first population-based, comprehensive assessments. Most subtypes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia/lymphoma (ALL/L) predominated among males, from twice higher incidence of T-cell ALL/L among males than among females (IRR = 2.20) to nearly equal IRs of acute promyelocytic leukemia (APL; IRR = 1.08). Compared with non-Hispanic whites, Hispanics had significantly higher incidence of B-cell ALL/L (IRR = 1.64) and APL (IRR = 1.28); blacks had lower IRs of nearly all AL subtypes. All ALL/L but only some AML subtypes were associated with a bimodal age pattern. Among AML subtypes, survival was highest for APL and AML with inv(16). B-cell ALL/L had more favorable survival than T-cell ALL/L among the young; the converse occurred at older ages. Limitations of cancer registry data must be acknowledged, but the distinct AL incidence and survival patterns based on the World Health Organization classification support biologic diversity that should facilitate etiologic discovery, prognostication, and treatment advances.


International Journal of Cancer | 1997

Non‐Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burden

Timothy R. Coté; Robert J. Biggar; Philip S. Rosenberg; Susan S. Devesa; Constance L. Percy; Frances Yellin; George Lemp; Catherine R. Hardy; James J. Geodert; William A. Blattner

We describe the anatomic and histologic presentation and prognosis of non‐Hodgkins lymphoma (NHL) among people with AIDS (PWA) and determine their contribution to the NHL burden. We linked AIDS and cancer registries in selected areas of the United States and compared NHL sites and histologies in PWA and non‐PWA, after adjusting for age, sex and ethnicity. Among 51,033 PWA, we found 2,156 cases of NHL (4.3%). Half of NHL cases occurring post‐AIDS were not reported to AIDS registries. NHL was part of an AIDS‐defining condition for 3.2% of all PWA; the relative risk of NHL with 3.5 years of another AIDS diagnosis was 165‐fold compared to non‐PWA within the cancer surveillance system. Of NHLs, 39% were high grade (vs. 12% among non‐PWA), 60% were nodal (vs. 74% among non‐PWA) and 15% had brain primaries (vs. 1% among non‐PWA). Excluding brain sites, extranodal sites were still 20% more common than expected. Relative risk was elevated for all histologic types, with the risk ranging from 652‐fold for high‐grade diffuse immunoblastic tumors and 261‐fold for Burkitts lymphomas to 113 for intermediate‐grade lymphoma to 14‐fold for low‐grade lymphoma. Survival among PWA with NHL was poor, and tumor grade had little impact. In high‐risk AIDS areas, AIDS‐related NHLs constitute a major share of the NHL burden. We conclude that NHL risk is considerably under‐estimated in AIDS registry data. The major differences between PWA and non‐PWA were the high frequency of brain lymphoma and the increase in high‐grade lymphomas in PWA. However, the grade of NHL did not influence the prognosis among PWA with lymphoma. The increasing risk of NHL in PWA has contributed substantially to the general increase in NHL rates in the United States since 1981. Int. J. Cancer 73:645–650, 1997.


Thyroid | 2011

Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006

Briseis Aschebrook-Kilfoy; Mary H. Ward; Mona M. Sabra; Susan S. Devesa

BACKGROUND The increasing incidence of thyroid cancer in the United States is well documented. In this study, we assessed the incidence patterns by histologic type according to demographic and tumor characteristics to further our understanding of these cancers. METHODS We used the National Cancer Institutes Surveillance, Epidemiology, and End Results (SEER) program for cases diagnosed during 1992-2006 to investigate patterns for the four major histologic types of thyroid cancer by gender, race/ethnicity, and age as well as registry, tumor stage, and size. RESULTS Among women, papillary thyroid cancer rates were highest among Asians (10.96 per 100,000 woman-years) and lowest among blacks (4.90 per 100,000 woman-years); follicular cancer rates did not vary substantially by race/ethnicity (p-values >0.05), medullary cancer rates were highest among Hispanics (0.21 per 100,000 woman-years) and whites (0.22 per 100,000 woman-years), and anaplastic rates were highest among Hispanics (0.17 per 100,000 woman-years). Among men, both papillary and follicular thyroid cancer rates were highest among whites (3.58 and 0.58 per 100,000 man-years, respectively), medullary cancer rates were highest among Hispanics (0.18 per 100,000 man-years), and anaplastic rates were highest among Asians (0.11 per 100,000 man-years). Racial/ethnic-specific rates did not vary notably across registries. In contrast to age-specific rates of papillary thyroid cancer that peaked in midlife (age 50), especially pronounced among women, rates for follicular, medullary, and anaplastic types continued to rise across virtually the entire age range, especially for anaplastic carcinomas. Female-to-male incidence rate ratios among whites decreased with age most steeply for the follicular type and least steeply for the medullary type; it was <1 until the very oldest ages for the anaplastic type. CONCLUSION We conclude that the similar age-specific patterns and lack of geographical variation across the SEER racial/ethnic groups indicate that detection effects cannot completely explain the observed thyroid cancer incidence patterns as variation in the amount or quality of healthcare provided has been shown to vary by SEER racial/ethnic groups, gender, and age. We find that the variations in age-specific patterns by gender and across histologic types are intriguing and recommend that future etiologic investigation focus on exogenous and endogenous exposures that are experienced similarly by racial/ethnic groups, more strongly among women, and distinctively by age.

Collaboration


Dive into the Susan S. Devesa's collaboration.

Top Co-Authors

Avatar

William F. Anderson

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joseph F. Fraumeni

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Katherine A. McGlynn

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martha S. Linet

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Philip S. Rosenberg

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Louise A. Brinton

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sam M. Mbulaiteye

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Patricia Hartge

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge